IBBI Registered Valuer Entity IBBI/RV-E/02/2020/123 · IRDAI category A surveyors+91 97370 33380bd@rakeshnarula.com
CallGet proposal
Industry playbook

Pharma company valuation in India: the Chemicals & Pharma playbook

Chemical and pharma firms own special process plants. They also own intangibles of high value. This playbook covers both.

Last updated

4 countriesCipla group companies valued
Chemical engineerslead plant valuations
IPdrugs under development valued

Pharma and chemical company valuation joins two kinds of work. One is a business valuation, using DCF and market multiples. The other is expert asset work. Process plants are valued on depreciated replacement cost. Intangibles are valued with a risk-adjusted DCF. These include product registrations and molecules still in development. Insurance values for these plants must reflect two things. Rebuild costs are high. And the standards are strict.

When does chemicals & pharma need a valuation?

TriggerWhat is neededRule or source
Purchase or sale of a unitEnterprise value, PPA and technical due diligenceInd AS 103
Insurance of plants and buildingsReinstatement valuePolicy terms
A chemical company goes insolventFair value and liquidation valueCIRP Regulations
Licence or transfer of molecules and brandsIntangible valuationIncome-tax, Ind AS 38

Which valuation method fits?

Asset or situationApproach we use
Running pharma businessDCF and market multiples
Process and API plantsDepreciated replacement cost, after a site visit by chemical engineers
Molecules in developmentRisk-adjusted DCF, weighted by the chance of success
Brands and registrationsRelief-from-royalty or excess earnings

How do you value a distressed acid plant?

A well-known acid maker became insolvent. Its value sat in special process plant. Few buyers could run it. Our chemical engineers checked the state of the plant. They also checked how it could be reused. Lenders then knew what a buyer would pay. Read the case study.

What is a pharma plant’s building worth to its insurer?

For a pharma group we valued buildings for insurance. Clean rooms and strict specs push up the rebuild cost. It is far above that of a normal factory building. Read the case study.

Can a drug that is not yet approved have a value?

Yes. For Unimark Remedies we valued the IP of drugs under development. We weighted the cash flows by the chance that each stage would work.

Pitfalls we see most often

  • Valuing clean rooms as normal buildings. The specification drives the cost.
  • Leaving out approvals. A plant’s value depends on its approvals and its inspection record.
  • Overstating the pipeline. The risk of failure must be shown clearly.
  • Missing clean-up liabilities. Most of all in chemical plants.
FAQ

Questions clients ask us

How is a pharma company valued?

We use DCF and market multiples for the business. Where needed, our experts also value the plants and the intangibles.

Can you value drug pipelines?

Yes. We use a risk-adjusted DCF, with a chance of success for each stage.

Do you value chemical plants for insurance?

Yes. Chemical engineers do it, on a reinstatement basis.

Which pharma clients has RNC worked for?

They include Cipla, with group companies in India, USA, South Africa and Uganda. We did sell-side work on units of Dr. Reddy’s and Cipla. We also worked for Unimark Remedies.

Get a quote

Request a chemicals & pharma valuation proposal

Tell us what needs valuing and why. You will hear back from a partner, not a sales desk.

  • Scoped proposal with fee and timeline, usually within one business day
  • Conflict check and NDA before any data changes hands
  • Reports signed under IBBI registration IBBI/RV-E/02/2020/123

Tell us about the assignment

Takes under a minute. All fields help us scope accurately.

    Service interested in *

    Your details stay confidential and are used only to prepare your proposal.